Gene promoter methylation signature predicts survival of head and neck squamous cell carcinoma patients
Gene promoter methylation signature predicts survival of head and neck squamous cell carcinoma patients
复制标题
DOI：
10.1080/15592294.2015.1137414
复制
发表时间：
2016-01-02
期刊：
影响因子：
3.7
通讯作者：
Hess, Jochen
中科院分区：
文献类型：
--
作者：
Kostareli, Efterpi;Hielscher, Thomas;Hess, Jochen
感染高危类型的人乳头瘤病毒(HPV)是目前公认的头颈部鳞状细胞癌(HNSCC)的预后标志，HNSCC是世界上最常见和最致命的人类恶性肿瘤之一。已经启动了临床试验，以解决HPV阳性HNSCC治疗降级的概念，最终目标是减少与治疗相关的毒性和对生活质量的长期影响。然而，HPV相关肿瘤主要局限于口咽鳞状细胞癌(OPSCC)，迫切需要为所有治疗失败的高风险患者建立可靠的生物标志物。对295例以非OPSCC为主(72.9%)、HPV16相关肿瘤患病率较低(8.8%)的患者进行MassARRAY分析，以确定先前建立的预后甲基化评分(MS)。Kaplan-Meier结果显示高MS与食管癌(P=0.0004)和非食管癌(P<0.05)的生存密切相关。
Infection with high-risk types of human papilloma virus (HPV) is currently the best-established prognostic marker for head and neck squamous cell carcinoma (HNSCC), one of the most common and lethal human malignancies worldwide. Clinical trials have been launched to address the concept of treatment de-escalation for HPV-positive HNSCC with the final aim to reduce treatment related toxicity and debilitating long-term impacts on the quality of life. However, HPV-related tumors are mainly restricted to oropharyngeal SCC (OPSCC) and there is an urgent need to establish reliable biomarkers for all patients at high risk for treatment failure. A patient cohort (n = 295) with mainly non-OPSCC (72.9%) and a low prevalence of HPV16-related tumors (8.8%) was analyzed by MassARRAY to determine a previously established prognostic methylation score (MS). Kaplan-Meier revealed a highly significant correlation between a high MS and a favorable survival for OPSCC (P = 0.0004) and for non-OPSCC (P